SCHEMBL4635182

SCHEMBL4635182

N#Cc1c(N2CC3C(N)C3C2)cccc1C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.50
DPP9 Q86TI2 3/20 0.50
DPP7 Q9UHL4 2/20 0.50
DPP8 Q6V1X1 1/20 0.50
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
PNMT P11086 1/20 0.35
GAA P10253 2/20 0.35
KMT2A Q03164 2/20 0.34
NOTUM Q6P988 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
P2RX7 Q99572 2/20 0.34
PREP P48147 1/20 0.34
CUL4A Q13619 1/20 0.33
CTSS P25774 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635272 0.81 KDM4E (0.57) DPP4DPP9DPP7DPP8KDM4E
SCHEMBL4636036 0.78 KDM4E (0.60) DPP4DPP9DPP7KDM4EALDH1A1
SCHEMBL16792970 0.77 KDM4E (0.58) DPP4DPP9DPP7DPP8KDM4E
SCHEMBL4635265 0.75 DPP4 (0.50) DPP4DPP9DPP7DPP8NOTUM
SCHEMBL3089450 0.74 EPHX2 (0.51) KDM4EALDH1A1HPGDHSD17B10L3MBTL1
SCHEMBL4635979 0.72 GRM1 (0.44) DPP4DPP9DPP7DPP8KDM4E
SCHEMBL2782425 0.71 DRD2 (0.42) DPP4DPP9DPP7DPP8KDM4E
SCHEMBL5798527 0.71 NOTUM (0.59) DPP4DPP9DPP7DPP8KDM4E
SCHEMBL1906819 0.71 AR (0.43) KDM4EALDH1A1HPGDL3MBTL1GAA
SCHEMBL4635419 0.70 DPP4 (0.49) DPP4DPP9DPP7DPP8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 DPP4 1/4885DPP9 5/4885DPP7 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.